Editorial: Rare musculoskeletal disorders: disease mechanisms and therapies de réir Lothar Seefried, Nathalie Bravenboer, Erik A. Imel

Faigh an téacs iomlán

FGF23, Hypophosphatemia, and Emerging Treatments de réir Erik A Imel, Andrew Biggin, Aaron Schindeler, Craig F Munns

Faigh an téacs iomlán

Using machine learning to detect sarcopenia from electronic health records de réir Xiao Luo, Haoran Ding, Andrea Broyles, Stuart J Warden, Ranjani N Moorthi, Erik A Imel

Faigh an téacs iomlán

X‐Linked Hypophosphatemia Caused by the Prevailing North American PHEX Variant c.*231A>G; Exon 13–15 Duplication Is Often Misdiagnosed as Ankylosing Spondylitis and Manifests in Bo... de réir Kathryn McCrystal Dahir, Margo Black, Gary S Gottesman, Erik A Imel, Steven Mumm, Cindy M Nichols, Michael P Whyte

Faigh an téacs iomlán

Sarcopenia, frailty and cachexia patients detected in a multisystem electronic health record database de réir Ranjani N. Moorthi, Ziyue Liu, Sarah A. El-Azab, Lauren R. Lembcke, Matthew R. Miller, Andrea A. Broyles, Erik A. Imel

Faigh an téacs iomlán

Unusual Cortical Phenotype After Hematopoietic Stem Cell Transplantation in a Patient With Osteopetrosis de réir Sonia Afshariyamchlou, Michelle Ng, Asmaa Ferdjallah, Stuart J. Warden, Paul Niziolek, Imranul Alam, Lynda E. Polgreen, Erik A. Imel, Paul Orchard, Michael J. Econs

Faigh an téacs iomlán

Mineral bone disorders and kidney disease in hospitalized children with sickle cell anemia de réir Anthony Batte, Philip Kasirye, Reagan Baluku, Sarah Kiguli, Robert Kalyesubula, Chandy C. John, Chandy C. John, Andrew L. Schwaderer, Erik A. Imel, Andrea L. Conroy, Andrea L. Conroy

Faigh an téacs iomlán

Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia de réir Mary D. Ruppe, Xiaoping Zhang, Erik A. Imel, Thomas J. Weber, Mark A. Klausner, Takahiro Ito, Maria Vergeire, Jeffrey S. Humphrey, Francis H. Glorieux, Anthony A. Portale, Karl Insogna, Munro Peacock, Thomas O. Carpenter

Faigh an téacs iomlán

Long-term safety in adults with X-linked Hypophosphatemia (XLH) treated with Burosumab, a fully human monoclonal antibody against FGF23: Final results of a phase 3 trial de réir Peter Kamenický, Anthony A. Portale, Tom Carpenter, Karine Briot, Erik A. Imel, Thomas Weber, Pisit Pitukcheewanont, Hae Il Cheong, Suzanne Jan de Beur, Yasuo Imanishi, Nobuaki Ito, Robin Lachmann, Hiroyuki Tanaka, Farzana Perwad, Lin Zhang, Alison Skrinar, Linda Rees, Karl L. Insogna

Faigh an téacs iomlán

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension de réir Karine Briot, Rachel K Crowley, Maria Luisa Brandi, Stuart H Ralston, Han-Wook Yoo, Peter Kamenický, Takuo Kubota, Nobuaki Ito, Martine Cohen-Solal, Richard Keen, Angela Williams, Muhammad K Javaid, Hiroyuki Tanaka, Robin H Lachmann, Karl Insogna, Richard Eastell, Yasuhiro Takeuchi, Anthony A Portale, Thomas O Carpenter, Hae Ii Cheong, Yasuo Imanishi, Steven Ing, Suzanne Jan de Beur, Farzana Perwad, Pisit Pitukcheewanont, Thomas J Weber, Annabel Nixon, Mark Nixon, Erik A Imel

Faigh an téacs iomlán